Hepatitis C & Drug User Health Intensive Preceptorship Application |
Thank you for your interest in the Hepatitis C & Drug User Health Intensive Preceptorship program! This program is provided by the Mount Sinai Institute for Advanced Medicine and funded through the New York State Department of Health (NYSDOH) AIDS Institute Clinical Education Initiative.
This clinical education program is in collaboration with the Respectful and Equitable Access to Comprehensive Healthcare (REACH) Program and the Institute for Liver Medicine (ILM) at Mount Sinai. This program provides an intensive experience for practicing clinicians including physicians, physician assistants, nurses, nurse practitioners, and certified nurse midwives in New York State. Through a combination of web-based didactic sessions and experiential training via tele-medicine, clinicians are able to enhance their Hepatitis C & Drug User Health treatment and care knowledge and competence to better serve their patients.
This clinical education program is in collaboration with the Respectful and Equitable Access to Comprehensive Healthcare (REACH) Program and the Institute for Liver Medicine (ILM) at Mount Sinai. This program provides an intensive experience for practicing clinicians including physicians, physician assistants, nurses, nurse practitioners, and certified nurse midwives in New York State. Through a combination of web-based didactic sessions and experiential training via tele-medicine, clinicians are able to enhance their Hepatitis C & Drug User Health treatment and care knowledge and competence to better serve their patients.
Program Overview:
Didactic portion
Two live webinars:
- Preceptorship Launch Webinar - August 20th, 2020 at 12:00pm-1:00pm
- Innovative Model of Primary Care for People Who Use Drugs - September 17th, 2020 at 4:00pm-5:00pm
Five courses completed online:
- Harm Reduction for Health Care Providers
- Buprenorphine in NYS: A Clinical Overview
- Naloxone: Preventing Overdose in the Community
- Treatment of Hepatitis C: New Test, New Drugs, and New Recommendations
- Hepatitis C and Drug Use: Addressing Screening, Treatment, and Stigma
Clinical Experience (via tele-medicine)
One-day of shadowing between September 18th-30th (day confirmed upon acceptance into the program)
- Shadow providers in a low threshold, harm reduction medical practice as well as a busy liver clinic
- Discuss best practices and sit in on patient visits
The REACH Program provides a patient-centered, harm reduction approach to primary care for persons who use alcohol and other drugs, and for individuals living with hepatitis C virus (HCV) infection.
Co-located within Mount Sinai Hospital’s Internal Medicine Associates, REACH provides comprehensive primary care services, including office-based buprenorphine treatment, stigma-free risk reduction counseling, HCV treatment, overdose response training, and psychosocial assessment and support including support groups. To learn more about the REACH program at Mount Sinai visit: www.ReachProgram.org
The ILM at Mount Sinai is a busy clinic which provides personalized care for acute and chronic liver diseases, including hepatitis C, hepatitis B, nonalcoholic fatty liver disease (NAFLD), liver cancer, and cirrhosis. ILM has a longstanding history of investigation and clinical trials of hepatitis C medications, and has treated over 1,500 patients with hepatitis C since 2014. To learn more about the ILM at Mount Sinai visit: https://www.mountsinai.org/care/liver-diseases
Space is limited! Applicants will be notified of acceptance by August 14, 2020.
In order to be considered for this program, please submit this application no later than August 12th, 2020. Accepted applicants must complete required Mount Sinai compliance trainings in order to be cleared to shadow expert clinicians, and must be given permission from their current supervisor to attend this preceptorship.
If you have any questions, please contact Emily Scognamiglio, MPH at emily.scognamiglio@mountsina